Evidence map›Paper›PMID 41784778›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Cancer prevention and screening].

Minna Voigtlaender, Judith Gebauer, Friederike Stoelzel, Barbara Kempf, Marianne Sinn, Nicole Skoetz

Abstract readEnglish AbstractReview
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Minna VoigtlaenderDepartment of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland. voigtlaender@dgho.de.
Judith GebauerDepartment of Oncology and University Cancer Center Leipzig, University Hospital Leipzig, Leipzig, Deutschland.
Friederike StoelzelUniversity Cancer Center Schleswig-Holstein, University Hospital Schleswig-Holstein, Kiel, Deutschland.
Barbara KempfBerliner Krebsgesellschaft e. V., Berlin, Deutschland.
Marianne SinnDepartment of Oncology, Hematology and BMT with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Deutschland.
Nicole SkoetzInstitut für Öffentliches Gesundheitswesen, Medizinische Fakultät und Uniklinik Köln, Universität zu Köln, Köln, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevention plays a key role in reducing the development and burden of disease and mortality in oncology. Primary, secondary and tertiary prevention should be understood as complementary levels where the preventive potential has not yet been sufficiently exploited. Primary prevention addresses modifiable risk factors, such as tobacco and alcohol consumption, obesity, lack of exercise, UV exposure and oncogenic infections. According to estimates, around 40% of new cancer cases in Europe could be prevented through consistent primary prevention measures. Secondary prevention comprises quality-assured, established cancer screening programs where the effectiveness has been proven but the utilization remains limited. Current developments include the introduction of organized lung cancer screening for defined high-risk populations. With the increasing number of cancer survivors, tertiary prevention is becoming increasingly more relevant; structured, multimodal and multiprofessional aftercare, rehabilitation and survivorship programs are essential for reducing recurrences and long-term somatic and psychosocial consequences. An effective cancer prevention requires the systematic integration of evidence-based measures into care, research and health policy. Medical and scientific societies actively contribute to strategic development in this area.

Indexed as

Early Detection of CancerNeoplasmsGermanyHumansPrimary PreventionRisk FactorsSecondary PreventionTertiary PreventionCancer screeningCancer survivorshipGerman Society of Hematology and Medical Oncology (DGHO)Prevention in oncologyPrimary, secondary and tertiary prevention

Identifiers

PMID41784778
PMCPMC13056771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.